Date |
|
Source |
Headline |
29th Oct 2020 | 7:00 am | GNW | Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020 |
28th Oct 2020 | 11:01 am | GNW | Verona Pharma plc : Update on AIM Delisting |
23rd Oct 2020 | 5:30 pm | RNS | Verona Pharma |
22nd Oct 2020 | 7:00 am | GNW | Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update |
13th Oct 2020 | 7:00 am | GNW | Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020 |
23rd Sep 2020 | 9:06 am | GNW | Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD |
21st Sep 2020 | 7:00 am | GNW | Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM |
17th Sep 2020 | 7:00 am | GNW | Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing |
16th Sep 2020 | 1:25 pm | GNW | Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease |
8th Sep 2020 | 7:00 am | GNW | Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 |
2nd Sep 2020 | 7:00 am | GNW | Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference |
26th Aug 2020 | 10:19 am | GNW | Verona Pharma plc: Grant of RADSUs and PDMR Dealings |
24th Aug 2020 | 7:00 am | GNW | Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020 |
19th Aug 2020 | 7:00 am | GNW | Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD |
14th Aug 2020 | 11:05 am | RNS | Second Price Monitoring Extn |
14th Aug 2020 | 11:00 am | RNS | Price Monitoring Extension |
14th Aug 2020 | 7:00 am | GNW | Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020 |
7th Aug 2020 | 3:46 pm | GNW | Verona Pharma plc: TR-1: Standard form for notification of major holdings |
4th Aug 2020 | 6:13 pm | GNW | Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights |
3rd Aug 2020 | 7:00 am | GNW | Verona Pharma Announces August 2020 Virtual Investor Conference Participation |
30th Jul 2020 | 10:52 am | GNW | Verona Pharma plc: TR-1: Standard form for notification of major holdings |
30th Jul 2020 | 7:00 am | GNW | Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update |
27th Jul 2020 | 7:01 am | GNW | Verona Pharma plc: TR-1: Standard form for notification of major holdings |
22nd Jul 2020 | 4:50 pm | GNW | Closing of Financing, Issued Share Capital and Total Voting Rights |
17th Jul 2020 | 5:47 pm | GNW | Verona Pharma plc: PDMR Dealings |
17th Jul 2020 | 7:00 am | GNW | Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription |
6th Jul 2020 | 4:04 pm | GNW | Verona Pharma plc: Issue of Equity and Total Voting Rights |
14th May 2020 | 7:00 am | GNW | Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program |
12th May 2020 | 1:11 pm | GNW | Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings |
1st May 2020 | 5:12 pm | GNW | Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference |
30th Apr 2020 | 7:00 am | GNW | Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 |
23rd Apr 2020 | 7:00 am | GNW | Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update |
16th Apr 2020 | 12:12 pm | GNW | Verona Pharma plc: Results of AGM |
8th Apr 2020 | 7:00 am | GNW | Update on AGM Procedure |
31st Mar 2020 | 7:00 am | GNW | Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD |
20th Mar 2020 | 11:28 am | GNW | Verona Pharma plc: Issue of Equity and Total Voting Rights |
17th Mar 2020 | 2:06 pm | RNS | Second Price Monitoring Extn |
17th Mar 2020 | 2:01 pm | RNS | Price Monitoring Extension |
16th Mar 2020 | 5:13 pm | GNW | 2019 Annual Report and Accounts and Notice of AGM |
5th Mar 2020 | 4:01 pm | GNW | Grant of Restricted Stock Units and PDMR Dealings |
27th Feb 2020 | 7:00 am | GNW | Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update |
21st Feb 2020 | 7:00 am | GNW | Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update |
14th Feb 2020 | 7:00 am | GNW | Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research |
7th Feb 2020 | 7:00 am | GNW | Holding(s) in Company TR-1: Standard form for notification of major holdings |
3rd Feb 2020 | 7:00 am | GNW | Verona Pharma Announces Senior Management Changes |
28th Jan 2020 | 7:00 am | GNW | Verona Pharma to Present at LSX World Congress 2020 |
17th Jan 2020 | 1:06 pm | GNW | Holding(s) in Company TR-1: Standard form for notification of major holdings |
13th Jan 2020 | 4:41 pm | RNS | Second Price Monitoring Extn |
13th Jan 2020 | 4:35 pm | RNS | Price Monitoring Extension |
13th Jan 2020 | 5:00 am | GNW | Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy |